GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Willow Biosciences Inc (TSX:WLLW) » Definitions » Shares Outstanding (EOP)

Willow Biosciences (TSX:WLLW) Shares Outstanding (EOP) : 127.35 Mil (As of Jun. 2024)


View and export this data going back to 1983. Start your Free Trial

What is Willow Biosciences Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Willow Biosciences's shares outstanding for the quarter that ended in Jun. 2024 was 127.35 Mil.

Willow Biosciences's quarterly shares outstanding increased from Mar. 2024 (126.96 Mil) to Jun. 2024 (127.35 Mil). It means Willow Biosciences issued new shares from Mar. 2024 to Jun. 2024 .

Willow Biosciences's annual shares outstanding increased from Dec. 2022 (123.72 Mil) to Dec. 2023 (124.44 Mil). It means Willow Biosciences issued new shares from Dec. 2022 to Dec. 2023 .


Willow Biosciences Shares Outstanding (EOP) Historical Data

The historical data trend for Willow Biosciences's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Willow Biosciences Shares Outstanding (EOP) Chart

Willow Biosciences Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.89 96.58 123.55 123.72 124.44

Willow Biosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 124.22 124.24 124.44 126.96 127.35

Competitive Comparison of Willow Biosciences's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Willow Biosciences's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Willow Biosciences's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Willow Biosciences's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Willow Biosciences's Shares Outstanding (EOP) falls into.



Willow Biosciences Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Willow Biosciences  (TSX:WLLW) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Willow Biosciences Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Willow Biosciences's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Willow Biosciences Business Description

Traded in Other Exchanges
Address
202, 1201 5th Street SW, Calgary, AB, CAN, T2R 0Y6
Willow Biosciences Inc is a Canadian biotechnology company. It has only one reportable segment engaged in developing and producing high-purity, plant-derived ingredients for consumer care, food and beverage, and pharmaceutical products. It has a geographic presence in Canada and the United states, in which it generates the majority of its revenue from the United states.
Executives
Christopher Kenneth Savile Director, Senior Officer
Travis Doupe Senior Officer
Patricia Ranija Choudhary Director
Sadiq Lalani Director
Barbara Elaine Munroe Director
Peter Seufer-wasserthal Director
Trevor Anthony Peters Director, Senior Officer
Troy Tapan Talkkari Senior Officer

Willow Biosciences Headlines

No Headlines